Thanks for the earlier note on PRTA ...great find
I see Lars Ekman is the Chairman of the Board and several ex Elan scientists are on board .
I know a PHD working in the Parkinson field that I 'll try and chat with this weekend .
But on first glance ...good early data ...looks promising
Re AMRN ...my posting history is on the AMRN Yahoo board for who ever wants to read it .
Specifically I owned a lot in 2010 , sold a lot in early 2011. Brought again after they were awarded a patent late 2011 and sold , by coincidence 1 day before they announced going it alone late 2012. Traded in and out since then
In other words I've been in and out of AMRN over the years .
Chk my posts late Oct 14 into early Nov 14 where I made the case for buying AMRN , then at 91c ...probably my largest number of AMRN shares I ever bt ....sold half on the run up to 3 to recoup cost ...chk my posts , so currently the shares I now own is free $.
I have had my loss's ...lost large on CLSN , but usually have small positions in up to 20 biotechs that I add to if positive data comes in . My biggest wins , PCYC , ESPR, REGN and yes AMRN .
My posting history on ESPR and AMRN is well documented on Yahoo boards.
If you are going to continue to try and insult me ...at least try and be accurate in what you post .
I was never intimidated by bullies as a kid on the playground , or as a worker on construction sites ....and certainly not by you on a message board.
The reason I'm here is because of well researched and presented posts by posters such as Tuttie_hvac.
RLYP has first mover advantage. Are we going to see a GILD vs ABBV Hep C type pricing war where Patiromer starts out at about $600 a mth ( suggested mthly costs of ZS-9 ) and then immediately drops their price 20% as soon as ZS-9 is launched..
This may make insurers demand that MD's try Patiromer first and only transfer patients who experience recurrence of hyperkalemia ( about 20% in the RASS inhibitor studies ) over to what may be the more expensive ZS-9
To remain long in ZSPH I need to understand the competitions pt of view and I'm more likely to find that on the RLYP board then on a ZSPH board
Regrading AMRN , message boards and Jesse Livermore . Posting on message boards can be a humbling experience and yes I was very gun ho on AMRN in the early days . I applied to be in Amarins Reduce It Trial and am prescribed their drug Vascepa , which I believe will show clinical benefit in their Outcome Trial.
But take heart ...You and Jesse Livermore have one thing in common . You both have a low opinion of me .
He reacts to my challenges on IHUB re AMRN with almost as much disdain as you do here on YMB re RLYP.
tuttle ...an interesting and informative post . Thks for contributing
Can you share any other bio tech positions you may have ?
You appear to do thorough research
Quick follow up
There is a Life Science Capital report out re dosing of Patirmoer and ZS-9 .. Have you seen it ?
From their report
" Moderate to severe HK on Patiromer recieved on average 35 gms of material each day, which includes 4 gms of Calcium and 10 gms of Sorbitol.
By contrast we estimate that 90% of those on ZS-9 will recieve 5-10 gms with a minority needing 15gms and is not given with sorbitol or other excipents.
The dosing load for patients is substantially lower with ZS-9 in terms of frequency and total amount of drug and other material. "
Gwin .. quick follow up re PRTA and NEOD001.
My PHD friend in the field thinks highly of the company , those working there and the early data on their pipeline. Says they are well funded with deep pockets backing them . Was concerned over recent run up in price and warned of a possible "sell the news " effect following the Tuesday ASCO presentation .
Amyloidosis and organ dysfunction are major challenges so lets hope they succeed for patients and investors .
Data on Tue will be presented by Dr Getz from the Mayo Clinic
I'm only in Biotech . Have held IBB ( and FBIOX ) for almost 4 yrs and traded in and out of individual Biotech issues over that same time period.
I tend to focus on anything to do with Kidney disease ( Wife did research in field at Yale ) and Heart disease ( family history and my own experience in a clinical trial ...inherited lipid disorder ) ...so if you so see anything in those areas please send a note .
Wife is interested in PRTA's work in Amylordosis also, as it affects her patients .
Can we settle this AMRN thing once and for all .
You keep writing that I owned " AMRN at $16 and followed it all the way down to .99c " which is factually not correct .
I live in Mill Valley CA . Name a Notary of your choice within an hr of where I live . Pay for their time to review my trading of AMRN since 2010....I'll take my IPad and access my trading accounts for them .
They can report to you and you can post the actual trades ...gains / loss's for all to see ...and then lets be done with it
My biggest loss if you need to know was in CLSN several years ago ...that took time to recover from.
Re Tuttles previous comments
You need to look at the prescribing PDF for Patiromer when approved . If you are looking at 35gms of material each day . Good luck with compliance for Chronic use if thats how much you need each day .
Tell you what . When approved I'll ask my wife for a 1 day sample ...be quite happy to send it on to you to try if you like .
The best thing about arguing with Golong ...is that it made you appear on this board .
Another perspective is welcome. ..........Re demand for product
IMHO based on the Nephrologist my wife has talked to , as well as my wife's experience dealing with HK patients ...as yes Golong she has at least one patient with unacceptably high Potassium levels every week .. there is great need for an alternative to the current SOC ( standard of care ) options.
They will be cautious on prescribing Patiromer to begin with because of the limited amount of long term.
So early prescribing trends on Patiromer may not be indicative of what to expect when ZS-9 is launched .
As an aside ..I actually posted thumbs up on Golongs posts before he started the personal attacks.
Why ? Because managing my Bio Tech investments is my full time job ...starting at 5am week days .
(I made my $ in real estate in Nth Ca and completed the sale my company ( small Corporation ) last yr.
Golong provided a foil for my investment thesis re ZSPH . Challenged me and made me dig deeper into researching ...so I wanted to encourage him to keep posting ...thus the thumbs up.
ZSPH , PRTO , ATRA ,CCXI , PRTA are the stocks I own that have applications in the Kidney disease area.
Following Golongs lead I also have positions in CEMP and TTPH .
I've owned BLUE, BMRN and RCPT for most of this year and more recently ITCI
I've also owned AMRN since late Oct 2014 and have maintained a big position in IBB for almost 4 yrs
I review all of these every trading day but usually only comment on those related to Kidney disease and Heart disease . I also commented on ESPR but no longer have a position .
I'm always interested in meeting anyone that can provide informed opinions... pro or con .. without the emotional drama
OT Interesting to review our debate over AMRN.
Back on March 4 2015
I suggested you take another look at it ....then at $1.54 ...and mentioned that I've had a large position since late Oct 14 at around 90c .
AMRN Closed Friday 5/29 /15 at $2.31 ....about 50% higher then when I suggested you look at it and what about 150% above my late Oct 14 purchase.
Believe you have a position in TGTX ....good data out at ASCO this weekend . Monday should be a good day for anyone holding that stock
Well its great to have a retired college prof on board . I'm retired also ...ex CEO / CFO small sub chapt S Corp that I sold to some key employees who had been with me 20 yrs or so. Some economics background UC Berkeley etc but mainly a lot of clients ( before I retired ) in biotech and hi tech in the SF bay area ..some of whom I remain in contact with.
I tend to look for areas of unmet need in fields I or my wife have experience in ...very data dependent ( ie I invest around impending data pts ...vs IPO's ) ...looking at cash on hand , expected need for capital raise , FDA hurdles ,expected end market and competition.
ESPR ( new version of Statin drugs ) was one of my biggest winners so far this year ...recently sold.
ZSPH has IMHO the best drug for Hyperkalemia ...altho behind RLYP in getting FDA approval.
PRTO has an interesting application for improving patency ( blood flow ) for dialysis patients ...small volatile stock.
AMRN is only for those who can tolerate a lot of risk ..most recent position from late Oct 14 . I'm prescribed their drug so maybe I'm biased :-).....believe it works and want it to work on me !
Just starting on PRTA ( thks to you ) Updated clinical data presentation June 12th . Maybe some data tomorrow at ASCO
phil ...Not sure if that question was directed a me but ...PHD friend knows Mgt , believes they are very talented and well funded BUT its all about the data ...and nearest real update I think is June 12 at EHA " Updated clinical data from the ongoing P 1/2 trial of NEOD001 "
phil believe the excitement is around their approach to clearing misfolded proteins in general.
My PHD friend tried to explain the approach ...talked about their approach to dosing etc .
Wife has tried to explain its relevance re her dialysis patients etc but frankly I'm new to PRTA so you will probably know more then I .
Looking forward to their CC today
Great data on Kidney disease patients .
My wife did research at Yale in CKD and when I first asked her about PRTA , I was asking about Parkinson's.
She was saying " Look at its application for late stage Kidney disease ....organ dysfunction "
This data is impressive , even more so because treatment appears well tolerated ...no dose limiting toxicities and no patients discontinued treatment due to drug related adverse events
All the patients ( small trial , only 15 renal patients ) , remain in trial and dose has been increased to 24 mg as of Dec 2
Long way to go but great news so far .
Hat Tip to Gwin for alerting me to PRTA
Brief follow up re Chronic Kidney disease and the importance of this data .
Many diabetics slowly lose kidney function . So theres a slow slide down ( from memory ....Stage 1 to stage 4 and eventually dialysis ( or transplant ) as the last option ...lays mans recall . Not an expert )
Those in late stage naturally fear / resist having to go on dialysis ...even when its in their best interest.
Wife deals with this weekly .
PRTA's treatment slows progression of loss of Kidney function in at least 60% of those on it ....more then double the benefit of the current SOC ( Standard of Care )....and they are increasing the dose so hopefully they will get an even better response rate .....and reasonably well tolerated
Imagine what this means to you if you are in mid - late stage kidney failure facing dialysis as your last option ( beside transplant )
Don't know what % of those in late stage Kidney failure are at that stage because of amyloidosis.
Will try and determine tonight .
First up tho ...as Dmiller mentioned ...data increases likely hood of VITAL trial showing benefit .
Thats in Phase 3 with at least 1 interim data read out planned.
On CC today mgt would not specific when to expect an interim read ( usually % of expected events ) ...but if trial enrolls faster then expected , data will be in earlier .
Because the data released today was great and treatment well tolerated , it will make it easier to recruit for VITAL.
If the Austrian co is only finishing P1 ...re Parkinsons ...they are years behind PRTA and their VITAL trial
JMO ( not an expert ...new to this field )
The FDA has been under pressure for some time to revise the guidelines re off label marketing and the marketing of dietary supplements .
As it stands right now , dietary supplement Omega 3's can market themselves as "heart healthy " where as Amarin can only market Vascepa for the reduction of very high TG's ( altho MD's are free to prescribe for high TG's etc ) .
So there really is a double standard here and huge stakes for all involved.
I'm not an attorney , but based on what I've read so far , I wouldn't dismiss Amarin's chances here .
Amarin's case has merit